Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    Zilebesiran

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Roche, Alnylam to Initiate Phase 3 Trial of Zilebesiran
    Roche, Alnylam to Initiate Phase 3 Trial of Zilebesiran

    31 Aug 2025

    // PRESS RELEASE

    https://www.roche.com/media/releases/med-cor-2025-08-30

    PRESS RELEASE
    31 Aug 2025
    Share Share
    Chugai in-licenses RNAi therapeutic zilebesiran for hyp.high cardiovascular risk
    Chugai in-licenses RNAi therapeutic zilebesiran for hyp.high cardiovascular risk

    20 Apr 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168662&sid=2

    PHARMABIZ
    20 Apr 2024
    Share Share
    Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran
    Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran

    07 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240407631982/en

    BUSINESSWIRE
    07 Apr 2024
    Share Share
    Alnylam to Webcast to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran
    Alnylam to Webcast to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran

    20 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240320967622/en

    BUSINESSWIRE
    20 Mar 2024
    Share Share
    Roche, Alnylam say blood pressure drug succeeds in mid-stage trial
    Roche, Alnylam say blood pressure drug succeeds in mid-stage trial

    06 Mar 2024

    // BIOPHARMA DIVE

    https://www.biopharmadive.com/news/alnylam-roche-hypertension-drug-study-results-zilebesiran/709303/

    BIOPHARMA DIVE
    06 Mar 2024
    Share Share
    Alnylam Reports Positive Results from Phase 2 Dose-Ranging Study of Zilebesiran
    Alnylam Reports Positive Results from Phase 2 Dose-Ranging Study of Zilebesiran

    07 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230907817269/en

    BUSINESSWIRE
    07 Sep 2023
    Share Share